Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension

In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase inhibitor baxdrostat reduced blood pressure in a dose-related manner.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-02, Vol.388 (5), p.395-405
Hauptverfasser:	Freeman, Mason W., Halvorsen, Yuan-Di, Marshall, William, Pater, Mackenzie, Isaacsohn, Jon, Pearce, Catherine, Murphy, Brian, Alp, Nicholas, Srivastava, Ajay, Bhatt, Deepak L., Brown, Morris J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aldosterone Aldosterone - blood Aldosterone - metabolism Aldosterone synthase Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Blood Pressure - drug effects Cardiology Clinical Medicine Clinical Medicine General Cortisol Cytochrome P-450 CYP11B2 - antagonists & inhibitors Diabetes Diuretics Double-Blind Method Endocrinology Endocrinology General Enrollments Humans Hypertension Hypertension - drug therapy Hypertension - etiology Lipids Nephrology Nephrology General Patients Placebos Potassium Prevention Regression analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase inhibitor baxdrostat reduced blood pressure in a dose-related manner.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2213169